Prudential PLC increased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 1,699.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 574,143 shares of the company's stock after buying an additional 542,231 shares during the period. Prudential PLC's holdings in Kenvue were worth $12,258,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Handelsbanken Fonder AB increased its holdings in Kenvue by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after acquiring an additional 21,222 shares in the last quarter. Alberta Investment Management Corp increased its stake in shares of Kenvue by 23.2% during the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after purchasing an additional 109,700 shares in the last quarter. Longbow Finance SA raised its position in shares of Kenvue by 5.0% during the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after purchasing an additional 13,287 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Kenvue by 143.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after buying an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. boosted its holdings in Kenvue by 1.4% in the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock worth $26,754,000 after buying an additional 17,466 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Down 0.1 %
KVUE stock traded down $0.03 during mid-day trading on Thursday, reaching $21.75. The company had a trading volume of 6,823,828 shares, compared to its average volume of 16,879,053. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a market capitalization of $41.57 billion, a price-to-earnings ratio of 41.13, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a fifty day simple moving average of $22.61 and a 200 day simple moving average of $22.42.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.77%. Kenvue's dividend payout ratio is currently 154.72%.
Wall Street Analyst Weigh In
A number of equities analysts have commented on KVUE shares. Citigroup reduced their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and reduced their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Redburn Atlantic initiated coverage on shares of Kenvue in a research note on Thursday. They set a "neutral" rating and a $23.50 target price on the stock. Canaccord Genuity Group increased their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Barclays boosted their price target on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of "Hold" and a consensus target price of $23.96.
View Our Latest Stock Analysis on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
